We recently published a list of 10 Best Multibagger Penny Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Xeris Biopharma Holdings Inc. (NASDAQ:XERS) stands against other best multibagger penny stocks to buy according to billionaires.
Penny stocks always seem like bargains for gaining exposure to some of the fastest-growing segments or spectacles, especially when popular stocks cost hundreds or thousands of dollars. Given that some cost as little as $2, they can be tempting for growing money quickly without spending much. While it’s possible to achieve significant returns while investing in companies with depressed stock prices, caution is always of utmost importance.
Low-priced stocks come with elevated levels of volatility as reduced liquidity makes them speculative, high-risk investments. Over the years, massive penny-stock scams have cheated thousands of investors out of millions of dollars, even as others have generated a fortune out of them. 2024 was one such year where investors betting on penny stocks generated a fortune as the overall stock market remained bullish. Explosive gains came into play as the equity outlook improved on expectations that the US Federal Reserve would cut interest rates.
Amid the current correction in the equity market after two years of blockbuster gains, penny stocks are increasingly becoming popular owing to their depressed valuations. President Donald Trump’s eldest son, Donald Trump Jr., and Lara Trump have already joined the fray in acquiring significant stakes in a conservative radio network, affirming renewed interest in thinly traded companies.
Nevertheless, in the face of rising trade tensions and the lowest consumer confidence seen in almost three years, US markets have faced significant fluctuations. Yet, despite these obstacles, the idea of penny stocks continues to hold relevance as investors hunt for low-cost options with potential for growth. Often linked with smaller or emerging companies, these stocks can present considerable upside when supported by robust financials and sound fundamentals.
It is possible to realize impressive returns by investing money into young firms with small market valuations or undervalued stock prices. That is especially the case at a time when President Trump is increasingly pushing for lower interest rates in the US. Like large-cap stocks, penny stocks tend to do well in low-interest rates environments as acquiring capital to accelerate operations and generate shareholder value becomes easier and more affordable for new and emerging companies.
For this article, we used a stock screener first to identify stocks priced under $5 that have posted huge gains over the past year (at least 100%). From the obtained dataset, we selected penny stocks with the highest percentage gains in stock performance over the past year (as of April 21). The list is ranked based on the number of billionaires that hold stakes in them, the data for which we sourced from Insider Monkey’s proprietary database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Is Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires?
A biotechnologist wearing lab coat, creating a unique formulation for a therapy.
Number of Billionaire Holders: 7
1-Year Gain as of April 21: 130.90%
Share Price as of April 21: $4.11
Xeris Biopharma Holdings Inc. (NASDAQ:XERS) is a biopharmaceutical company that develops and commercializes innovative therapies across endocrinology, neurology, and gastroenterology segments. The company focuses on developing products using its proprietary XeriSol and XeriJect technology platforms. The stock is up by 130.90% over the past year thanks to continued momentum in its commercial business.
Recorlev is driving growth in the commercial business for the treatment of Cushing’s syndrome, which has shown 118% growth; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis. The three products were the catalyst behind Xeris Biopharma’s delivery of strong full-year 2024 results, characterized by a record revenue of $203 million, an improvement from $163.9 million in 2023.
In addition, Xeris Biopharma Holdings Inc. (NASDAQ:XERS) sentiments significantly increased the company’s net loss, narrowing to $54.8 million in FY2024 from $62.3 million in 2023. The company boasts of an impressive revenue growth trajectory that has reached 22.7% over the past 12 months. It’s already projecting a 30% revenue growth in 2025 of between $255 and $275 million, driven by the substantial upside potential of XP8121, a treatment for hypothyroidism.
Overall, XERS ranks 4th on our list of best multibagger penny stocks to buy according to billionaires. While we acknowledge the potential of XERS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than XERS but that trades at less than 5 times its earnings check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
